Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer

Colorectal cancer is one of the most common cancers worldwide. The prognosis of patients with metastatic colorectal cancer in recent years has increased from 5 months with best supportive care to nearly 2 years with chemotherapy combined with bevacizumab, an antivascular endothelial growth factor mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Zoratto, Federica, Rossi, Luigi, Zullo, Angelo, Papa, Anselmo, Zaccarelli, Eleonora, Tomao, Luigi, Giordani, Erika, Colonna, Maria, Baiano, Giovanni, Tomao, Silverio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460673/
https://www.ncbi.nlm.nih.gov/pubmed/23055745
http://dx.doi.org/10.2147/OTT.S30581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460673/
https://www.ncbi.nlm.nih.gov/pubmed/23055745
http://dx.doi.org/10.2147/OTT.S30581

Ejemplares similares